Skip to main content
X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.120
-0.050 (-1.58%)
Nov 13, 2026, 4:00 PM EST - Market closed

X4 Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
16.9635.112.56---
Revenue Growth
-50.08%1273.21%----
Gross Profit
13.8729.361.76---
Operating Income
-73.15-79.88-141.4-107.52-88.08-75.35
Net Income
-80.52-79.2-37.45-101.17-96.41-102.64
Earnings Per Share
-0.66-1.87-5.59-17.07-45.53-119.59
EPS Growth
------

Revenue by Geography
Chart
Fiscal Year
TTMFY 2025FY 2024
Period EndingSep '26 Dec '25 Dec '24
United States
9.86.52.6
United Kingdom
7.128.6-
Total
16.935.12.6

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
187.7253102.06114.22121.7281.79
Total Debt
77.277.2978.0958.2838.4239.79
Net Cash (Debt)
110.51175.7123.9755.9483.342
Net Cash Growth
146.46%632.93%-57.14%-32.85%98.32%4.33%
Net Cash Per Share
0.904.153.589.4439.3448.94

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-76.1-85.62-130.9-96.51-77.1-70.91
Capital Expenditures
---0.33-0.06-0.1-0.62
Free Cash Flow
-76.1-85.62-131.23-96.57-77.21-71.52
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
81.77%83.60%68.83%---
Operating Margin
-431.29%-227.50%-5529.96%---
Pretax Margin
-474.71%-225.44%-1452.48%---
Profit Margin
-474.74%-225.56%-1464.61%---
FCF Margin
-448.68%-243.84%-5132.07%---

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
18.789.9648.93---